| INTRODUC TI ONLong-term immunosuppression administered to solid organ transplant (SOT) recipients is associated with an increased risk of infectious complications. Current immunosuppressive drugs are mostly aimed at suppressing T cell-mediated adaptive immunity, potentially giving innate immunity a crucial role in protecting against pathogens in the transplant setting. 1,2Mannose-binding lectin (MBL) is a soluble pattern recognition molecule critically involved, along with ficolins, in complement activation through the lectin pathway. 3 This C-type lectin is mainly synthesized in the liver, although extrahepatic sources also exist. By binding to N-acetyl-glucosamine and d-mannose residues on microbial surfaces, MBL activates MBL-associated serine proteases, which cleave complement factors C4 and C2 and induce the formation of